LEADER 06094cam a2200649Ii 4500
001 801259
003 TR_AnAIT
005 20260123022127
006 m o d
007 cr cnu||||nuuu
008 190124s2019 nyu ob 001 0 eng d
020 |a9781315173269|q(electronic bk.)
020 |a1315173263|q(electronic bk.)
020 |a9781351700337|q(electronic bk.)
020 |a1351700332|q(electronic bk.)
020 |a9781351700344
020 |a1351700340
020 |a9781351700320|q(electronic bk. ;|qMobipocket)
020 |a1351700324|q(electronic bk. ;|qMobipocket)
020 |z1138043230
020 |z9781138043237
020 |z9781138043190
020 |z1138043192
035 |a(OCoLC)1083266860|z(OCoLC)1083458907
035 |a(OCoLC-P)1083266860
040 |aOCoLC-P|beng|erda|epn|cOCoLC-P
041 |aeng
049 |aTürk Tarih Kurumu Kütüphanesi
050 4|aTP248.2
072 7|aSCI|x013060|2bisacsh
072 7|aTEC|x009010|2bisacsh
072 7|aSCI|x010000|2bisacsh
072 7|aSOC|x026000|2bisacsh
072 7|aJHB|2bicssc
082 04|a660.6|223
100 1 |aStevens, Tina,|eauthor.
245 10|aBiotech juggernaut :|bhope, hype, and hidden agendas of entrepreneurial bioscience /|cTina Stevens and Stuart Newman.
264 1|aNew York :|bRoutledge,|c2019.
300 |a1 online resource (1 volume)
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
505 0 |aCover; Half Title; Title Page; Copyright Page; Dedication; Table of Contents; Acknowledgments; Prologue: A Shared Encounter; References; Chapter 1: Introduction: The Biotech Juggernaut; The Rise of the Biotech Industry; Ethics, Dissent, and the Dream of Responsible Science; The Specter of Eugenics; Technological Pragmatism Replaces Moral Concern; The Jesse Gelsinger Story: The Human Cost of Hyped Technology; The Return of Gene Therapy; The Rise of Entrepreneurial Biology: Diamond v. Chakrabarty and the Bayh-Dole Act; Commerce Eclipsing Criticism; What Is to Come (in this Book?
505 8 |aIn the Future?)Notes; Sources Consulted for Chapter 1; Chapter 2: The Dawn of GM Humans; The Gene Bubble; The New Developmental Biology and Dreams of a Scientific Eugenics; Human Modification -- for Better or Worse; Sources Consulted for Chapter 2; Chapter 3: California Cloning: The Campaign; Clouding Issues at the Origin of CIRM; Enter California; Notes; Sources Consulted for Chapter 3; Chapter 4: California Cloning: The Aftermath; Conflicts of Interest in the Running of CIRM; The Egg Wars; Notes; Sources Consulted for Chapter 4; Chapter 5: Synthetic Biology: Extreme Genetic Engineering.
505 8 |aThe Politics of Synthetic BiologyCoda; Notes; Sources Used for Chapter 5; Chapter 6: The Road to Gattaca; Paving the Road to Gattaca; Signposts Ignored: The Fallacy of Genetic Determinism; Misdirecting Signposts on the Road to Gattaca; Avoiding Gattaca?; Notes; Sources Consulted for Chapter 6; Chapter 7: Concluding Reflections; Sources Used for Chapter 7; Appendices; Appendix A: Position Paper on Human Germ Line Manipulation; Appendix B: Memo to CIRM Standards Working Group Challenging CIRM's 2013 Move to Change Egg Donation Reimbursement Policy.
505 8 |aAppendix C: Testimony by Sindy Wei, MD to the California Senate Health Committee re AB 926Appendix D: Testimony by Jennifer Schneider, MD to the California Senate Health Committee re AB 926; Appendix E: Testimony of Raquel Cool, Co-Founder, We Are Egg Donors, in Opposition To AB 2531; Appendix F: Email to SFSU Faculty from UCSF Center for Reproductive Health, September 21, 2017; Appendix G: Open Letter to President's Bioethics Commission from Fifty-Eight Civil Society Groups, December 16, 2010; Appendix H: Civil Society Letter to East Bay City Councils, 2011.
505 8 |aAppendix I: List of Civil Society Organizations Concerning Emerging BiotechnologiesGlossary; List of Abbreviations and Terms; Index.
520 |aBiotech Juggernaut: Hope, Hype, and Hidden Agendas of Entrepreneurial BioScience relates the intensifying effort of bioentrepreneurs to apply genetic engineering technologies to the human species and to extend the commercial reach of synthetic biology or "extreme genetic engineering." In 1980, legal developments concerning patenting laws transformed scientific researchers into bioentrepreneurs. Often motivated to create profit-driven biotech start-up companies or to serve on their advisory boards, university researchers now commonly operate under serious conflicts of interest. These conflicts stand in the way of giving full consideration to the social and ethical consequences of the technologies they seek to develop. Too often, bioentrepreneurs have worked to obscure how these technologies could alter human evolution and to hide the social costs of keeping on this path. Tracing the rise and cultural politics of biotechnology from a critical perspective, Biotech Juggernaut aims to correct the informational imbalance between producers of biotechnologies on the one hand, and the intended consumers of these technologies and general society, on the other. It explains how the converging vectors of economic, political, social, and cultural elements driving biotechnology's swift advance constitutes a juggernaut. It concludes with a reflection on whether it is possible for an informed public to halt what appears to be a runaway force.
588 |aOCLC-licensed vendor bibliographic record.
650 0|aBiotechnology.
650 0|aGenetic engineering.
650 0|aBiotechnology industries.
650 7|aSCIENCE|xChemistry|xIndustrial & Technical.|2bisacsh
650 7|aTECHNOLOGY & ENGINEERING|xChemical & Biochemical.|2bisacsh
650 7|aSCIENCE|xBiotechnology.|2bisacsh
650 7|aSOCIAL SCIENCE|xSociology|xGeneral.|2bisacsh
700 1 |aNewman, Stuart|q(Stuart A.),|eauthor.
856 40|3Taylor & Francis|uhttps://www.taylorfrancis.com/books/9781315173269
856 42|3OCLC metadata license agreement|uhttp://www.oclc.org/content/dam/oclc/forms/terms/vbrl-201703.pdf
901 |aTaylor & Francis